Plant Name: Acacia pruinosa
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| PDE5A; | |
| LCK; FYN; MAPK1; MAPK14; MAPK3; | |
| CA2; CA4; CA12; CA7; | |
| NR1H4; | |
| HMGCR; | |
| USP2; | |
| SLCO1B3; SLCO1B1; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Oxidoreductase | HMGCR | HMG-CoA reductase | P04035 | CHEMBL402 |
| Phosphodiesterase 5 | PDE5A | Phosphodiesterase 5A | O76074 | CHEMBL1827 |
| Protein Kinase | LCK | Tyrosine-protein kinase LCK | P06239 | CHEMBL258 |
| Protein Kinase | FYN | Tyrosine-protein kinase FYN | P06241 | CHEMBL1841 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | MAPK14 | MAP kinase p38 alpha | Q16539 | CHEMBL260 |
| Protein Kinase | MAPK3 | MAP kinase ERK1 | P27361 | CHEMBL3385 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 2.264E-10 | 3.725E-06 | CA2, CA7, FYN, HMGCR, LCK, MAPK1, MAPK14, MAPK3, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 9.062E-10 | 6.578E-06 | CA12, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.860E-08 | 2.101E-04 | CA12, CA2, CA4, CA7 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 5.735E-08 | 2.498E-04 | CA2, CA7, MAPK1, MAPK14, MAPK3, NR1H4 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 8.851E-08 | 2.753E-04 | CA12, CA2, CA4, CA7 |
| MF | Unclassified; | GO:0004707; MAP kinase activity | 2.917E-07 | 5.293E-04 | MAPK1, MAPK14, MAPK3 |
| MF | Unclassified; | GO:0004708; MAP kinase kinase activity | 3.644E-07 | 6.103E-04 | MAPK1, MAPK14, MAPK3 |
| MF | GO:0005488; binding | GO:0042610; CD8 receptor binding | 9.167E-07 | 1.026E-03 | FYN, LCK |
| BP | GO:0065007; biological regulation | GO:0030641; regulation of cellular pH | 2.011E-06 | 1.860E-03 | CA2, CA7, MAPK1, MAPK3 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.748E-06 | 2.137E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015721; bile acid and bile salt transport | 3.221E-06 | 2.314E-03 | NR1H4, SLCO1B1, SLCO1B3 |
| BP | GO:0050896; response to stimulus | GO:0031663; lipopolysaccharide-mediated signaling pathway | 3.564E-06 | 2.314E-03 | MAPK1, MAPK14, MAPK3 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 3.564E-06 | 2.314E-03 | CYP1A2, MAPK1, MAPK3 |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 3.613E-06 | 2.314E-03 | FYN, LCK, MAPK1, MAPK3 |
| BP | GO:0009987; cellular process | GO:0090170; regulation of Golgi inheritance | 5.494E-06 | 2.918E-03 | MAPK1, MAPK3 |
| MF | GO:0005488; binding | GO:0001784; phosphotyrosine residue binding | 5.177E-06 | 2.918E-03 | LCK, MAPK1, MAPK3 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.494E-06 | 2.918E-03 | CYP1A2, CYP2C9 |
| BP | GO:0051179; localization | GO:0072584; caveolin-mediated endocytosis | 9.151E-06 | 4.151E-03 | MAPK1, MAPK3 |
| BP | GO:0032501; multicellular organismal process | GO:0061308; cardiac neural crest cell development involved in heart development | 9.151E-06 | 4.151E-03 | MAPK1, MAPK3 |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.273E-05 | 5.435E-03 | FYN, LCK, MAPK3 |
| BP | GO:0032501; multicellular organismal process | GO:0060440; trachea formation | 1.372E-05 | 5.636E-03 | MAPK1, MAPK3 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.372E-05 | 5.636E-03 | CYP1A2, CYP2C9 |
| BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 1.888E-05 | 7.084E-03 | L3MBTL1, LCK, MAPK1, MAPK3 |
| BP | GO:0002376; immune system process | GO:0002741; positive regulation of cytokine secretion involved in immune response | 1.919E-05 | 7.084E-03 | MAPK14, MAPK3 |
| MF | GO:0005488; binding | GO:0042608; T cell receptor binding | 1.919E-05 | 7.084E-03 | FYN, LCK |
| MF | GO:0005488; binding | GO:0042609; CD4 receptor binding | 1.919E-05 | 7.084E-03 | FYN, LCK |
| BP | GO:0032501; multicellular organismal process | GO:0060020; Bergmann glial cell differentiation | 2.558E-05 | 8.438E-03 | MAPK1, MAPK3 |
| BP | GO:0050896; response to stimulus | GO:0009605; response to external stimulus | 2.793E-05 | 8.813E-03 | CYP1A2, FYN, HMGCR, MAPK1, MAPK14, MAPK3, NR1H4, USP2 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.881E-05 | 8.963E-03 | CA2, CA4, SLCO1B1, SLCO1B3 |
| BP | GO:0032502; developmental process | GO:0042473; outer ear morphogenesis | 3.286E-05 | 9.803E-03 | MAPK1, MAPK3 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.465E-09 | 3.225E-07 | SLCO1B1; CA2; SLCO1B3; NR1H4; HMGCR |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 3.787E-08 | 1.489E-06 | LCK; MAPK1; FYN; MAPK14; MAPK3 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.373E-09 | 1.621E-07 | CA12; CA2; CA4; CA7 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 8.446E-08 | 2.491E-06 | TBXAS1; MAPK1; FYN; MAPK14; MAPK3 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.253E-07 | 2.957E-06 | LCK; MAPK1; FYN; MAPK14; MAPK3 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 4.558E-07 | 8.963E-06 | MAPK1; FYN; MAPK14; MAPK3 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 4.456E-06 | 6.884E-05 | MAPK1; FYN; MAPK14; MAPK3 |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 7.113E-06 | 9.326E-05 | LCK; MAPK1; FYN; MAPK3 |
| hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 4.667E-06 | 6.884E-05 | MAPK1; FYN; MAPK3 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.526E-05 | 2.710E-04 | MAPK1; MAPK14; MAPK3 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 4.159E-05 | 3.467E-04 | MAPK1; MAPK14; MAPK3 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 2.059E-05 | 2.430E-04 | MAPK1; MAPK14; MAPK3 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 4.335E-05 | 3.467E-04 | MAPK1; MAPK14; MAPK3 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 4.515E-05 | 3.467E-04 | MAPK1; FYN; MAPK3 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 3.059E-05 | 3.008E-04 | MAPK1; MAPK14; MAPK3 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.142E-04 | 6.418E-04 | MAPK1; MAPK14; MAPK3 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 8.376E-05 | 5.491E-04 | MAPK1; MAPK14; MAPK3 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 1.044E-04 | 6.418E-04 | MAPK1; MAPK14; MAPK3 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 4.701E-05 | 3.467E-04 | MAPK1; MAPK14; MAPK3 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 1.142E-04 | 6.418E-04 | MAPK1; MAPK14; MAPK3 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.511E-04 | 7.042E-04 | MAPK1; FYN; MAPK3 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 7.077E-05 | 4.912E-04 | MAPK1; MAPK14; MAPK3 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.318E-04 | 6.763E-04 | MAPK1; MAPK14; MAPK3 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.471E-04 | 7.042E-04 | MAPK1; MAPK14; MAPK3 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.246E-04 | 6.682E-04 | MAPK1; MAPK14; MAPK3 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.552E-04 | 7.042E-04 | CYP2C9; MAPK1; MAPK3 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.811E-04 | 7.913E-04 | MAPK1; MAPK14; MAPK3 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.903E-04 | 8.019E-04 | MAPK1; MAPK14; MAPK3 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.577E-04 | 9.503E-04 | MAPK1; MAPK14; MAPK3 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 2.249E-04 | 8.847E-04 | MAPK1; FYN; MAPK3 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 2.577E-04 | 9.503E-04 | MAPK1; MAPK14; MAPK3 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 3.255E-04 | 1.090E-03 | MAPK1; FYN; MAPK3 |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 3.124E-04 | 1.084E-03 | MAPK1; MAPK14; MAPK3 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 3.527E-04 | 1.095E-03 | MAPK1; MAPK14; MAPK3 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 5.022E-04 | 1.519E-03 | MAPK1; PDE5A; MAPK3 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 5.756E-04 | 1.698E-03 | MAPK1; MAPK14; MAPK3 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 6.048E-04 | 1.741E-03 | MAPK1; MAPK14; MAPK3 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 8.855E-04 | 2.322E-03 | MAPK1; MAPK14; MAPK3 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 8.730E-04 | 2.322E-03 | MAPK1; FYN; MAPK3 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 9.902E-04 | 2.486E-03 | MAPK1; MAPK14; MAPK3 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.706E-03 | 3.479E-03 | MAPK1; MAPK14; MAPK3 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.465E-03 | 3.323E-03 | MAPK1; MAPK3 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.277E-03 | 3.075E-03 | MAPK1; MAPK3 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.323E-03 | 3.122E-03 | MAPK1; MAPK3 |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 1.465E-03 | 3.323E-03 | MAPK1; MAPK3 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.102E-03 | 2.709E-03 | MAPK1; MAPK3 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.563E-03 | 3.415E-03 | MAPK1; MAPK3 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.716E-03 | 3.479E-03 | MAPK1; MAPK3 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 3.048E-03 | 5.213E-03 | MAPK1; MAPK3 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 3.926E-03 | 6.261E-03 | MAPK1; MAPK3 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.159E-03 | 3.859E-03 | MAPK1; MAPK3 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.769E-03 | 3.479E-03 | MAPK1; MAPK3 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 4.004E-03 | 6.300E-03 | MAPK1; MAPK3 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 7.695E-03 | 1.081E-02 | MAPK1; MAPK3 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 3.187E-03 | 5.297E-03 | MAPK1; MAPK3 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 3.474E-03 | 5.694E-03 | MAPK1; MAPK3 |
| hsa04350 | TGF-beta signaling pathway_Homo sapiens_hsa04350 | 2.845E-03 | 4.938E-03 | MAPK1; MAPK3 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.043E-03 | 3.827E-03 | MAPK1; MAPK3 |
| hsa04713 | Circadian entrainment_Homo sapiens_hsa04713 | 3.622E-03 | 5.855E-03 | MAPK1; MAPK3 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.159E-03 | 3.859E-03 | MAPK1; MAPK3 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 8.343E-03 | 1.158E-02 | MAPK1; MAPK3 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 4.083E-03 | 6.339E-03 | MAPK1; MAPK3 |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 1.769E-03 | 3.479E-03 | MAPK1; MAPK3 |
| hsa04724 | Glutamatergic synapse_Homo sapiens_hsa04724 | 5.169E-03 | 7.721E-03 | MAPK1; MAPK3 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.769E-03 | 3.479E-03 | MAPK1; MAPK3 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 4.242E-03 | 6.501E-03 | MAPK1; MAPK3 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.716E-03 | 3.479E-03 | CYP2C9; CYP1A2 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.822E-03 | 3.525E-03 | MAPK1; MAPK3 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 9.710E-03 | 1.332E-02 | MAPK1; MAPK3 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 7.589E-03 | 1.079E-02 | MAPK1; MAPK3 |
| hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 1.232E-02 | 1.653E-02 | MAPK1; MAPK3 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.690E-02 | 3.307E-02 | CYP2C9; TBXAS1; CYP1A2; HMGCR |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.594E-02 | 2.067E-02 | MAPK1; MAPK3 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 9.397E-04 | 2.410E-03 | MAPK1; MAPK3 |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 1.729E-02 | 2.217E-02 | MAPK1; MAPK3 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 5.991E-03 | 8.621E-03 | MAPK1; MAPK3 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 5.527E-03 | 8.153E-03 | MAPK1; MAPK3 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.092E-02 | 1.481E-02 | MAPK1; MAPK3 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 3.118E-03 | 5.255E-03 | MAPK1; MAPK3 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.932E-02 | 2.451E-02 | MAPK1; MAPK3 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.507E-02 | 1.976E-02 | MAPK1; MAPK3 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 4.095E-02 | 4.881E-02 | MAPK1; MAPK3 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.563E-03 | 3.415E-03 | CYP2C9; TBXAS1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.339E-02 | 1.776E-02 | MAPK1; MAPK3 |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 5.711E-03 | 8.319E-03 | MAPK1; MAPK3 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.714E-03 | 4.780E-03 | CYP2C9; CYP1A2 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 6.858E-04 | 1.882E-03 | MAPK1; MAPK3 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.931E-03 | 3.676E-03 | CYP2C9; CYP1A2 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 6.204E-04 | 1.743E-03 | MAPK1; MAPK3 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.159E-03 | 3.859E-03 | CYP2C9; CYP1A2 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 3.419E-04 | 1.090E-03 | MAPK1; MAPK3 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 2.959E-04 | 1.058E-03 | MAPK1; MAPK3 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.138E-04 | 8.698E-04 | CA2; CA4 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.419E-04 | 1.090E-03 | CYP2C9; CYP1A2 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.734E-02 | 4.496E-02 | CYP1A2 |
| hsa05340 | Primary immunodeficiency_Homo sapiens_hsa05340 | 3.459E-02 | 4.207E-02 | LCK |
| hsa04966 | Collecting duct acid secretion_Homo sapiens_hsa04966 | 2.535E-02 | 3.149E-02 | CA2 |
| hsa00900 | Terpenoid backbone biosynthesis_Homo sapiens_hsa00900 | 2.070E-02 | 2.599E-02 | HMGCR |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.741E-03 | 7.173E-03 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | MAPK14; MAPK14 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MAPK14 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | TBXAS1; HMGCR |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1 |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | MAPK14 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HMGCR |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HMGCR |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1; PDE5A |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | PDE5A; MAPK14 |
| NA: NA | Hyperlipidemia | NA | HMGCR |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| NA: NA | Cardiovascular disease | NA | HMGCR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | PDE5A; HMGCR |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | HMGCR |
| NA: NA | Rheumatold arthritis | NA | MAPK14 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | PDE5A; PDE5A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | MAPK14 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HMGCR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PDE5A |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | TBXAS1; PDE5A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MAPK14 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | HMGCR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | HMGCR |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | MAPK14 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | LCK |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; MAPK14 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| K00-K95: Diseases of the digestive system | Chemotherapy or radiotherapy-induced mucositis | K12.3, R52, G89 | HMGCR |
| A00-B99: Certain infectious and parasitic diseases | HBV infection | B16, B18.0, B18.1 | HMGCR |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MAPK14 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | PDE5A; PDE5A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Elevated CRP | E78.0 | HMGCR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | HMGCR |
| N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TBXAS1; MAPK14 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | HMGCR |
| NA: NA | Edema | NA | CA2 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2 |
| NA: NA | Dyslipidemia | NA | HMGCR |
| NA: NA | Inflammatory diseases | NA | MAPK14 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | PDE5A |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | TBXAS1 |
| NA: NA | Raynaud's disease | NA | PDE5A; PDE5A |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | MAPK14 |
| NA: NA | Acute respiratory distress syndrome | NA | MAPK14 |